APA (7th ed.) Citation

X, G., C, Z., & Y, W. (2026). Persistent residual inflammatory risk at 1 month after contemporary PCI: Rationale for routine hsCRP reassessment and dual-target therapy. Frontiers in immunology, 17, 1840386. https://doi.org/10.3389/fimmu.2026.1840386

Chicago Style (17th ed.) Citation

X, Gong, Zhou C, and Wu Y. "Persistent Residual Inflammatory Risk at 1 Month After Contemporary PCI: Rationale for Routine HsCRP Reassessment and Dual-target Therapy." Frontiers in Immunology 17 (2026): 1840386. https://doi.org/10.3389/fimmu.2026.1840386.

MLA (9th ed.) Citation

X, Gong, et al. "Persistent Residual Inflammatory Risk at 1 Month After Contemporary PCI: Rationale for Routine HsCRP Reassessment and Dual-target Therapy." Frontiers in Immunology, vol. 17, 2026, p. 1840386, https://doi.org/10.3389/fimmu.2026.1840386.